No debera ser necesario vivir a base de batidos y barritas para continuar el tratamiento
This is about saving hearts Who qualifies: Adults with established CVD + overweight/obesity (BMI 27 kg/m) The drug: Semaglutide 2.4mg once-weekly subcutaneous injection (GLP-1 RA) Titrated to maintenance dose Adjunct to lifestyle counselling & standard care Why NICE said yes: Reduces risk of MACE (heart attack, stroke, CV death) in this population Cost-effective within NHS thresholds (20,00030,000/QALY) Commercial agreement already in place with NHS The pathway is simple: Assess CVD risk Lifestyle counselling Add semaglutide Monitor This follows SELECT trial data showing ~20% MACE reduction independent of weight loss We are watching GLP-1s redefine cardiovascular medicine in real time From diabetes obesity now primary CV risk reduction Whats next
Gesualdo C, Balta C, Platania CB, Trotta MC, Herman H, Gharbia S, et al
Hims also has a much wider range of monotherapies and other telehealth offerings, including mental health care, premature ejaculation treatment, and more, which well briefly address after our main comparison of ED medication offerings
Induction of necrosis has been proposed as the main toxicity effect based on in vitro experiments on human skin fibroblast models
I travel from Wellington because Majestic Aesthetics actually delivers results. Renee D., Wellington, FL If youre serious about losing weight, this clinically supervised program is the way to go